Last reviewed · How we verify
Switch to Triumeq
Switch to Triumeq is a Antiretroviral combination therapy (NRTI + INSTI) Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).
Triumeq is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication.
Triumeq is a medication used to treat HIV-1 infection. It contains the active ingredients bictegravir, emtricitabine, and tenofovir alafenamide, which work together to inhibit the replication of the virus.
At a glance
| Generic name | Switch to Triumeq |
|---|---|
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Drug class | Antiretroviral combination therapy (NRTI + INSTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Triumeq combines abacavir (a nucleoside reverse transcriptase inhibitor), lamivudine (a nucleoside reverse transcriptase inhibitor), and dolutegravir (an integrase strand transfer inhibitor). These three agents work synergistically to block different steps of the HIV replication cycle, preventing the virus from multiplying and reducing viral load in infected individuals.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based dosing)
Common side effects
- Hypersensitivity reaction (abacavir-related)
- Nausea
- Diarrhea
- Headache
- Insomnia
- Fatigue
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals (PHASE4)
- Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations (PHASE4)
- Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (PHASE3)
- SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over (PHASE4)
- Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC (NA)
- Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Switch to Triumeq CI brief — competitive landscape report
- Switch to Triumeq updates RSS · CI watch RSS
- McGill University Health Centre/Research Institute of the McGill University Health Centre portfolio CI
Frequently asked questions about Switch to Triumeq
What is Switch to Triumeq?
How does Switch to Triumeq work?
What is Switch to Triumeq used for?
Who makes Switch to Triumeq?
What drug class is Switch to Triumeq in?
What development phase is Switch to Triumeq in?
What are the side effects of Switch to Triumeq?
What does Switch to Triumeq target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + INSTI) drugs
- Target: All drugs targeting HIV reverse transcriptase, HIV integrase
- Manufacturer: McGill University Health Centre/Research Institute of the McGill University Health Centre — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in adolescents and children (weight-based dosing)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing